Why is $CCCC moving today? · SEC 8-K archive

$CCCC SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $CCCC: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $CCCC filing catalyst

Why did $CCCC trigger an AI stock catalyst alert?

$CCCC triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +0.5/10). Headline: C4 Therapeutics Reports Q3 Net Loss of $0.16/Share, Cash Runway into Late 2028. Key points: - Q3 revenue was $8.5M vs. $11.2M in Q3 2025; net loss narrowed to $21.8M or $0.16 per share vs. $32.2M or $0.44 per share. - Cash, cash equivalents and marketable securities stood at $274.7M as of Q3 close, providing runway through the end of 2028. - Phase 2 MOMENTUM trial on track to complete enrollment in 1Q 2027 with initial ORR data expected in 2H 2027.

How did $CCCC stock react after the SEC filing?

After the SEC 8-K for $CCCC, observed market reaction: T0 price $3.12. Past moves do not guarantee future results.

Where can I get real-time $CCCC SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $CCCC via Telegram and the VIP Web Terminal from €10/month.

$CCCC

$CCCC – C4 Therapeutics Reports Q3 Net Loss of $0.16/Share, Cash Runway into Late 2028

C4 Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $CCCC

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (+0.5 / 10)

Q3 revenue was $8.5M vs. $11.2M in Q3 2025; net loss narrowed to $21.8M or $0.16 per share vs. $32.2M or $0.44 per share.
Cash, cash equivalents and marketable securities stood at $274.7M as of Q3 close, providing runway through the end of 2028.
Phase 2 MOMENTUM trial on track to complete enrollment in 1Q 2027 with initial ORR data expected in 2H 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →